(OTCQB: MYDX) – MyDx Inc. is a science and technology company that owns MyDx™- which is “is a simple and affordable portable analyzer that will detect the chemicals we cannot see.” This analyser will help detect and analyse how consumers feel in direct relation to the profile of the cannabis. According to the company, “MyDx™ uses nanotechnology to accurately measure chemicals” and its aim is to make people live better by understanding the components in the food and drinks that they consume. When people are aware of the specific contents of what they eat and how it makes them feel, they can develop a diet that makes them happier overall.
MyDx Inc. was formed by Daniel Rida Yazbeck on December 20, 2012 and is headquartered in San Diego, CA. Daniel Yazbeck is also a majority shareholder in the company – holding approximately 44.5% of the outstanding voting shares. The Company was originally known as Brista Corp. and its intention was to produce crumb rubber tile from recycled truck and automotive tires, which it later abandoned. A series of changes and merger with its wholly owned subsidiary led to the name change to MyDx Inc.
Earlier this month, MYDX had taken an aggressive position in filing a restraining order because it believed it continued to receive conversation notices when it had fully satisfied the obligations to certain convertible notes.
Management & Governance (Please note- there are not any current, known disputes within MyDx management team)
Daniel Yazbeck is the seed investor and creator of the MyDx Analyzer. He holds a Master of Science degree in Medicinal Chemistry and has almost 15 years of experience at Pfizer Pharmaceuticals and Panasonic. In his previous roles, he worked as a scientist and engineer for developing new products and forming strategic partnerships in electronics-healthcare industry. He is the Chief Financial Officer in addition to his role as Chief Executive Officer. Daniel is supported by two Vice Presidents, each heading Operations and Software Engineering. The company board of directors has seven members according to its SEC filings.
The Company has experienced a series of changes to its management which have proved disruptive and has had adverse effects on its financial conditions including but not limited to inability to timely file quarterly reports. MyDx is exposed to key person risk.
Industry Overview & Competitive Positioning
The biotech industry is extremely volatile because of the nature of significant scientific expenditure and operations that are required to develop a product from initial stage to market. The industry emerged in the early 1970s and the primary purpose is to improve and enhance the quality of human life. The players range from traditional drug manufactures to medical endeavours for via creation and combination of DNA, to discovery of treatments and therapies for diabetes, cancer and other range of diseases.
MYDX is focused on developing a technology that analyses the effects that our consumption (food, drugs, alcohol) has on us, and this information will “Empower you to live a healthier life by revealing the purity of what you eat, drink & inhale in the palm of your hands and in real time”.
As demand for high quality cannabis extracts continues to rise and the legal marijuana sector expands, the industry revenue is expected to increase
In addition to general market risks, the following are specific risks to an investment in MyDx Inc.:
- Liquidity Risk: Being a penny stock, the shares have low liquidity and large bid asks spreads. Investors will not be able to readily sell their shares and the market price might be negatively affected.
- Going Concern Risk: It is an early-stage company with very limited operating and financial history and no current revenue generating product. The company expects to continue to sustain losses and it is no certainty that it will generate revenues in the near term.
- Financing Risk: The company currently has low cash balance and it is unlikely to procure additional funding at favourable financing terms. This will greatly hamper the ability to continue to develop MyDx™ to commercial viability.
- Obsolescence Risk: The technology industry is rapidly developing and changing. If a new technology is developed by another firm during the development stage of MyDx™, the effect would be negative on MyDx Inc and the Company may be unable to compete effectively.
- Abandonment Risk: Given that the Company has a history of abandoning its original business plan, unforeseen hurdles may cause it to change or abandon its existing business plan.
- Third Party Risk: The Company depends on specific manufacturers, and distribution channels and it does not appear that there are any long-term purchase or service agreements with these third parties.
MyDx Inc revenue for Q32016 was $134,240 (2015Q3: $219,180), a decline of 39% quarter on quarter.
Net loss continues to be volatile and similarly, net cash flow from operations has continued to remain negative. The Company has however been conscious to reduce its cash burn by over 80% and secured a five-year initial $2.5m licensing deal with a partner in China to distribute its two new sensors – the two new sensors launched were AquaDx™ and OrganaDx™ sensors. Its first app, the CannaDx™, was also one of the top apps on the Apple iOS App Store Charts.
As of close of business on March 27, 2017, MYDX shares closed at $0.02 on a traded volume of 126,207,215. The stock gained $0.0041 from its previous day close, an increase of 23.98%. The current market cap is $9.66m.
On March 17, 2017 the company announced that it has resolved its key liabilities position and is poised to unlock its true value as it now focuses on the next phase of its business – “to use Community driven data to develop unique formulations for the Cannabis Market”.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Sina Yilu, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 3 months. This article was written by me from publicly available information and the Company’s SEC filings. The article expresses my own opinions and there is no business relationship with any company whose stock is mentioned in the article.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way, endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.